ALAMEDA, Calif., May 24, 2023 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at William Blair's 43rd Annual Growth Stock Conference on Wednesday, June 7, 2023.
Event: | William Blair's 43rd Annual Growth Stock Conference |
Date: | Wednesday, June 7, 2023 |
Time: | 9:20am CT/ 7:20am PT |
A webcast of the presentation will be available by visiting the investors' section of the company's website at www.penumbrainc.com. The webcast will be available on the company's website for at least two weeks following the event.
About Penumbra
Penumbra, Inc., headquartered in Alameda, California, is a global healthcare company focused on innovative therapies. Penumbra designs, develops, manufactures and markets novel products and has a broad portfolio that addresses challenging medical conditions in markets with significant unmet need. Penumbra supports healthcare providers, hospitals and clinics in more than 100 countries. For more information, visit www.penumbrainc.com and connect on Twitter and LinkedIn.
Investor Relations
Penumbra, Inc.
510-995-2461
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$293.17 |
| Daily Change: | -2.79 -0.94 |
| Daily Volume: | 117,077 |
| Market Cap: | US$11.480B |
November 05, 2025 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
